GILEAD SCIENCES SL

As a global company, we offer access and operate in many regions around the world.

Through open dialogue, partnerships, and awareness, we aim to remove barriers and improve clinical trial participation experiences.

Indian Patent Office to hear objections against Gilead Sciences' patent claims on HIV drug Lenacapavir, with concerns over affordable access and ending AIDS. Sankalp opposes, citing the drug's previously known compound status under India’s Patent Act. Experts argue for public health priority over pharma profits, challenging Gilead's monopoly to enable generic competition.

iTeos Therapeutics' mid-stage trial results show its drug, when combined with GSK's immunotherapy, shrank lung tumors in twice as many patients compared to GSK's therapy alone. The trial raised safety concerns due to three treatment-related deaths from immune-related inflammation. Despite previous failures of TIGIT-targeting drugs, iTeos' data could rekindle interest in the target, with further data expected to clarify the combination's impact on survival and disease progression.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

Gilead Sciences' Phase III PURPOSE 2 study shows twice-yearly lenacapavir injection reduced HIV infections by 96%, outperforming daily Truvada for HIV prevention. The study's interim analysis recommended offering open-label lenacapavir to all participants. Gilead plans global regulatory filings by end of 2023, aiming for a 2025 launch.

Gilead Sciences' lenacapavir, an HIV treatment repurposed as a twice-yearly preventive shot, reduced HIV infection risk by 96% in a trial involving over 3200 individuals. The drug's high cost as a treatment ($3450/month) raises concerns about its affordability as PrEP. Gilead plans to submit lenacapavir for FDA approval by end of 2024, aiming to make it accessible globally.

Marengo Therapeutics and Gilead collaborate on a Phase I/II study combining STAR0602 (Invikafusp alfa) with Trodelvy for metastatic HR+/HER2- breast cancer and TNBC, aiming to explore a novel therapeutic strategy.

99.9% of participants in the lenacapavir group did not acquire HIV in the PURPOSE 2 trial, with 2 incident cases among 2,180 participants. The trial demonstrated lenacapavir's 96% reduction in HIV infections compared to background incidence and its superiority to once-daily Truvada. Gilead will offer open-label lenacapavir to all participants and plans regulatory filings by end of 2024.

Twice-yearly lenacapavir injections reduced HIV infections by 96% in a phase 3 trial, outperforming daily PrEP pills. Gilead plans global regulatory filings by end of 2024 for potential 2025 launch.